Abbott Labs (ABT) PT Raised to $117 at Bernstein SocGen Group
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $105.97 -2.18%
Rating Summary:
26 Buy, 9 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 25 | Down: 24 | New: 33
Rating Summary:
26 Buy, 9 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 25 | Down: 24 | New: 33
Join SI Premium – FREE
Bernstein SocGen Group analyst Lee Hambright raised the price target on Abbott Labs (NYSE: ABT) to $117.00 (from $110.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Quest Diagnostics (DGX) PT Raised to $245 at UBS
- Roivant Sciences (ROIV) PT Raised to $52 at Jefferies
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
